SCHEMBL4878713

SCHEMBL4878713

NCC(Cl)(C(=O)O)C(=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 5/20 0.45
MAPK1 P28482 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HIF1A Q16665 3/20 0.41
GSK3B P49841 2/20 0.41
TRPA1 O75762 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 2/20 0.40
MAPT P10636 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.40
PARP1 P09874 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292151 0.81 CES1 (0.45) CES1MAPK1ALDH1A1HIF1AGSK3B
SCHEMBL3345380 0.79 AKR1C3 (0.41)
SCHEMBL30354083 0.78 CES1 (0.52) CES1MAPK1ALDH1A1HIF1AGSK3B
SCHEMBL3344473 0.78 ERCC5 (0.42) MAPK1ALDH1A1TSHRL3MBTL1SMN1; SMN2
SCHEMBL8346930 0.76 CES1 (0.44) CES1MAPK1ALDH1A1HIF1AGSK3B
SCHEMBL3349728 0.74 CES1 (0.47) CES1MAPK1ALDH1A1HIF1AGSK3B
SCHEMBL10616915 0.74 HIF1A (0.52) CES1MAPK1ALDH1A1HIF1AGSK3B
SCHEMBL8594235 0.74 CES1 (0.50) CES1MAPK1ALDH1A1HIF1AGSK3B
SCHEMBL3345467 0.73 CES1 (0.45) CES1MAPK1ALDH1A1HIF1ACYP3A4
SCHEMBL4878721 0.73 CES1 (0.45) CES1MAPK1ALDH1A1HIF1AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459472-B2 Aryl and heteroaryl compounds, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2008-12-02 US disclosed
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use VTVX HOLDINGS I LLC 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use CYP2F1, CYP3A43, PNPO CES1 430/4885MAPK1 4143/4885ALDH1A1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.